The global market for artificial intelligence in pharmaceuticals is projected to reach $28.63 billion by 2034, primarily fueled by advancements in drug discovery processes.
According to a report by Polaris Market Research, AI is increasingly integral to various stages of drug discovery, including identifying drug targets, analyzing protein structures, and simulating chemical interactions, which surpasses traditional laboratory methods. The financial implications of this shift are substantial, as the costs associated with bringing a drug to market can range from $161 million to $2 billion, with a low success rate in clinical trials. This economic burden is driving the pharmaceutical industry to adopt AI solutions to enhance success rates and reduce costs.
Natural language processing is currently leading the market, accounting for 35.64% of revenue in 2025, as it effectively translates complex clinical data into understandable formats for both medical professionals and patients. Additionally, machine learning and generative AI are gaining traction, particularly in designing new molecular structures and predicting their therapeutic efficacy. Cloud-based services are also becoming popular, especially among startups that wish to bypass significant infrastructure investments.
AI's influence extends to clinical trials as well, where it enhances patient recruitment through the mining of electronic health records and genomic data. Predictive analytics play a crucial role in identifying risks and optimizing dosing in real time. Notably, there is a significant opportunity in addressing rare diseases, which have historically been neglected due to low development returns. For example, the rising prevalence of Alzheimer’s disease underscores the urgent need for breakthroughs, as the number of affected individuals could soar to 13.8 million by 2050, with associated costs potentially reaching $1 trillion.
Regionally, North America currently dominates the market with nearly half of the revenue share, but the Asia Pacific region is expected to experience the fastest growth, driven by government initiatives in countries like China, India, and South Korea. Despite these advancements, challenges such as a shortage of skilled workers, high implementation costs, and resistance from some healthcare providers remain significant hurdles to overcome.